A phaseI/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung cancer
Phase 1
Recruiting
- Conditions
- on-Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000013202
- Lead Sponsor
- Kansai Medical University Hirakata Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
1)Interstitial pneumonia or pulmonary fibrosis detectable on chest Xp 2)History of radiation therapy for chest 3)With hemosputum 4)With active bleeding 5)Symptomatic brain metastasis 6)With active infectious disease 7)History of serious disease condition 8)With massive pleural effusion or ascitis 9)History of active double cancer 10)need to operation 11) History of pregnancy or lactation 12)History of active psychological disease 13) History of drug allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method Safety, Response Rate, Disease Control Rate, Overall Survival